Sept. 23, 2022 – Southwest Mississippi Regional Medical Center (SMRMC) had big plans for how it could reach more patients in need in the communities that it serves. But that all changed when drug companies started restricting access to 340B drug pricing program discounts to SMRMC and other safety-net hospitals. “We had plans of extending our services to expand mental health … [Read more...]
Faces of 340B: Community Pharmacy Partnerships Aid in the Cancer Care Cause
April 22, 2022 – A bell rings and a round of applause is heard. A patient is marking the end of their cancer treatments at St. Anthony Regional Hospital in Carroll, Iowa. The patient knows the chemotherapy and radiation treatments they received from the St. Anthony Regional Cancer Center enabled them to reach this special day. What they may not realize is that the hospital’s … [Read more...]
Faces of 340B: Community Pharmacy Partnerships Benefit Patients with Diabetes
Oct. 28, 2021 – Courtney Riddle’s patient was at a family-owned pharmacy in Magnolia, Ark., where she always picked up her medications, including the diabetes drug Jardiance that was helping to control her blood sugar levels. The patient’s out-of-pocket cost typically was $16.43 for a month’s supply, but this time it was much different. The patient received a note that said … [Read more...]
Diabetes Care Bears the Brunt of Drugmakers’ 340B Restrictions
Sept. 23, 2021– The eight pharmaceutical companies that are restricting the discounts they offer through the 340B drug pricing program are blocking safety-net hospitals’ access to savings on a wide range of prescription drugs. But perhaps in no area is this more evident than when looking at the prices of diabetes drugs and the levels of lost 340B resources that otherwise would … [Read more...]
Merck Plan to Withhold 340B Discounts Adds to Threat to Diabetes Patients
August 26, 2021 - The global pharmaceutical manufacturer Merck is the latest company to announce it will stop offering 340B discounts to hospitals on drugs dispensed to patients at community pharmacies. The move comes three months after the federal government warned drug companies that such actions are unlawful under the 340B drug pricing program statute. Merck will become the … [Read more...]